{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:45:04Z","timestamp":1791510304508,"version":"4.3.4"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.critrevonc.2024.104557","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T16:20:23Z","timestamp":1732292423000},"page":"104557","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Concomitant chemotherapy in trimodal treatment of patients with muscle invasive bladder cancer: A systematic review of prospective trials"],"prefix":"10.1016","volume":"205","author":[{"given":"Camille","family":"Baudelin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Dinart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Hennequin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Teyssonneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Meynard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam-Son","family":"Vuong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e9lix","family":"Lefort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Baboudjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilhem","family":"Roubaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.critrevonc.2024.104557_bib1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration","volume":"48","author":"Advanced Bladder Cancer (ABC) Meta-analysis Collaboration","year":"2005","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104557_bib2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.critrevonc.2014.11.007","article-title":"A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC)","volume":"94","author":"Arcangeli","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104557_bib3","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0360-3016(00)00444-2","article-title":"Chemoradiotherapy for muscle invading bladder carcinoma. Final report of a single institutional organ-sparing program","volume":"47","author":"Arias","year":"2000","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104557_bib4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/(SICI)1097-0142(19970701)80:1<115::AID-CNCR15>3.0.CO;2-0","article-title":"Radical chemoradiotherapy for elderly patients with bladder carcinoma invading muscle","volume":"80","author":"Arias","year":"1997","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104557_bib5","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/cncr.25667","article-title":"Gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer: Long-term cumulative results of 2 prospective single-institution studies","volume":"117","author":"Caffo","year":"2011","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104557_bib6","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.radonc.2016.09.006","article-title":"Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: A pooled individual data analysis of eight phase I-II trials","volume":"121","author":"Caffo","year":"2016","journal-title":"Radio. Oncol. J. Eur. Soc. Ther. Radio. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104557_bib7","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0360-3016(03)00124-X","article-title":"Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer","volume":"56","author":"Chen","year":"2003","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104557_bib8","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1470-2045(20)30607-0","article-title":"Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials","volume":"22","author":"Choudhury","year":"2021","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104557_bib9","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1200\/JCO.2010.31.5721","article-title":"Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer","volume":"29","author":"Choudhury","year":"2011","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104557_bib10","first-page":"903","article-title":"Conservative treatment with transurethral resection, neoadjuvant chemotherapy followed by radiochemotherapy in stage T2-3 transitional bladder cancer","volume":"8","author":"Cobo","year":"2006","journal-title":"Clin. Transl. Oncol. Publ. Fed. Span. Oncol. Soc. Natl. Cancer Inst. Mex."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104557_bib11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/JCO.18.00537","article-title":"Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil\/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG\/RTOG 0712-A Randomized Phase II Trial","volume":"37","author":"Coen","year":"2019","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104557_bib12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/030089169307900112","article-title":"Conservative treatment for T2-T4 bladder cancer with primary chemotherapy and radiotherapy: a pilot study","volume":"79","author":"Cruciani","year":"1993","journal-title":"Tumori"},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104557_bib13","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1002\/cncr.20654","article-title":"Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results","volume":"101","author":"Danesi","year":"2004","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104557_bib14","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0360-3016(94)90003-5","article-title":"Organ-sparing treatment of advanced bladder cancer: a 10-year experience","volume":"30","author":"Dunst","year":"1994","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104557_bib15","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/S0090-4295(96)00019-2","article-title":"Combination transurethral resection, systemic chemotherapy, and pelvic radiotherapy for invasive (T2-T4) bladder cancer unsuitable for cystectomy: a phase I\/II Southwestern Oncology Group study","volume":"47","author":"Einstein","year":"1996","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104557_bib16","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1046\/j.1464-410X.1997.00221.x","article-title":"Combined chemotherapy and radiation with selective organ preservation for muscle-invasive bladder carcinoma. A single-institution phase II study","volume":"80","author":"Fellin","year":"1997","journal-title":"Br. J. Urol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104557_bib17","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.eururo.2017.03.019","article-title":"Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review","volume":"73","author":"Fonteyne","year":"2018","journal-title":"Eur. Urol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104557_bib18","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.eururo.2023.01.016","article-title":"Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score","volume":"83","author":"Galsky","year":"2023","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104557_bib19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.radonc.2006.09.001","article-title":"Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group","volume":"81","author":"Gogna","year":"2006","journal-title":"Radio. Oncol. J. Eur. Soc. Ther. Radio. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104557_bib20","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0360-3016(03)00718-1","article-title":"RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy","volume":"57","author":"Hagan","year":"2003","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104557_bib21","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.eururo.2022.04.017","article-title":"Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial","volume":"82","author":"Hall","year":"2022","journal-title":"Eur. Urol."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104557_bib22","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/cncr.21048","article-title":"Acute and late morbidity in the treatment of advanced bladder carcinoma with accelerated radiotherapy, carbogen, and nicotinamide","volume":"103","author":"Hoskin","year":"2005","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104557_bib23","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1200\/JCO.1993.11.11.2150","article-title":"Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study","volume":"11","author":"Housset","year":"1993","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104557_bib24","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ijrobp.2013.06.2044","article-title":"Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK\/01\/004)","volume":"87","author":"Huddart","year":"2013","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104557_bib25","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2019.11.001","article-title":"Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy \u00b1 Chemotherapy in the BC2001 Phase III Randomised Controlled Trial","volume":"77","author":"Huddart","year":"2020","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104557_bib26","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/00005392-200101000-00014","article-title":"Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study","volume":"165","author":"Hussain","year":"2001","journal-title":"J. Urol."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104557_bib27","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1038\/sj.bjc.6601852","article-title":"Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer","volume":"90","author":"Hussain","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104557_bib28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1464-410X.1989.tb05125.x","article-title":"Concurrent Adriamycin and Radiotherapy in Locally Advanced Bladder Cancer","volume":"63","author":"Jakse","year":"1989","journal-title":"British Journal of Urology"},{"key":"10.1016\/j.critrevonc.2024.104557_bib29","doi-asserted-by":"crossref","unstructured":"James N.D., Liu W., Pirrie S., et al. TUXEDO: A phase I\/II trial of cetuximab with chemoradiotherapy in muscle-invasive bladder cancer. BJU Int. Published online July 31, 2022. doi:10.1111\/bju.15864.","DOI":"10.1111\/bju.15864"},{"issue":"19","key":"10.1016\/j.critrevonc.2024.104557_bib30","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1056\/NEJM199311043291903","article-title":"Selective bladder preservation by combination treatment of invasive bladder cancer","volume":"329","author":"Kaufman","year":"1993","journal-title":"N. Engl. J. Med"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104557_bib31","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1634\/theoncologist.5-6-471","volume":"5","author":"Kaufman","year":"2000","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104557_bib32","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.urology.2008.09.036","article-title":"Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy","volume":"73","author":"Kaufman","year":"2009","journal-title":"Urology"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104557_bib33","first-page":"1201","article-title":"The efficacy of trimodal chemoradiotherapy with gemcitabine and cisplatin as a bladder-preserving strategy for the treatment of muscle-invasive bladder cancer: a single-arm phase II study","volume":"52","author":"Kobayashi","year":"2022","journal-title":"Jpn J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104557_bib34","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.radonc.2005.01.007","article-title":"Phase II study of radiochemotherapy with vinblastine in invasive bladder cancer. Radiother Oncol J Eur Soc Ther","volume":"75","author":"Kragelj","year":"2005","journal-title":"Radio. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104557_bib35","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijrobp.2009.10.038","article-title":"Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97-015)","volume":"79","author":"Lagrange","year":"2011","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104557_bib36","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ijrobp.2008.11.030","article-title":"Induction cisplatin and fluorouracil-based chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer","volume":"75","author":"Lin","year":"2009","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2024.104557_bib37","article-title":"Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis","volume":"11","author":"M F","year":"2021","journal-title":"Front Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104557_bib38","article-title":"Impact of Age on Outcomes of Patients With Pure Carcinoma In Situ of the Bladder: Multi-Institutional Cohort Analysis","volume":"20","author":"M F","year":"2022","journal-title":"Clin. Genitourin. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104557_bib39","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.ijrobp.2016.12.018","article-title":"A Phase 1\/2 Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation After Transurethral Surgery for Noncystectomy Candidates With Muscle-Invasive Bladder Cancer (Trial NRG Oncology RTOG 0524)","volume":"97","author":"Michaelson","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104557_bib40","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(13)70255-9","volume":"14","author":"Mitin","year":"2013","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104557_bib41","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1007\/s12032-010-9544-x","article-title":"Concurrent administration of liposomal doxorubicin improves the survival of patients with invasive bladder cancer undergoing hypofractionated accelerated radiotherapy (HypoARC)","volume":"28","author":"Panteliadou","year":"2011","journal-title":"Med Oncol. North. Lond. Engl."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104557_bib42","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.urology.2003.09.018","article-title":"Concurrent chemoradiotherapy for clinical stage T2 bladder cancer: report of a single institution","volume":"63","author":"Peyromaure","year":"2004","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104557_bib43","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","volume":"79","author":"Pfister","year":"2021","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104557_bib44","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.eururo.2014.02.038","article-title":"Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review","volume":"66","author":"Ploussard","year":"2014","journal-title":"Eur. Urol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104557_bib45","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1159\/000020020","article-title":"Concomitant radiotherapy and carboplatin in locally advanced bladder cancer","volume":"36","author":"Radosevic-Jelic","year":"1999","journal-title":"Eur. Urol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104557_bib46","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/1097-0142(20000901)89:5<1089::AID-CNCR18>3.0.CO;2-9","article-title":"Long term follow-up of combined radiochemotherapy for locally advanced bladder carcinoma","volume":"89","author":"Retz","year":"2000","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104557_bib47","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1080\/02656736.2022.2109763","article-title":"Tetramodal therapy with transurethral resection followed by chemoradiation in combination with hyperthermia for muscle-invasive bladder cancer: early results of a multicenter phase IIB study","volume":"39","author":"Riesterer","year":"2022","journal-title":"Int J. Hyperth. J. Eur. Soc. Hyperthermic Oncol. North Am. Hyperth. Group"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104557_bib48","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/0360-3016(90)90449-T","article-title":"Treatment of advanced transitional cell carcinoma of the bladder with irradiation and concomitant 5-fluorouracil infusion","volume":"18","author":"Rotman","year":"1990","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104557_bib49","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/0360-3016(90)90498-9","article-title":"Combined 5-fluorouracil and irradiation for transitional cell carcinoma of the urinary bladder","volume":"19","author":"Russell","year":"1990","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104557_bib50","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.urolonc.2008.07.005","article-title":"Combined modality treatment with bladder preservation for muscle invasive bladder cancer","volume":"28","author":"Sabaa","year":"2010","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104557_bib51","unstructured":"SEER National Cancer Institute. Bladder Cancer \u2014 Cancer Stat Facts SEER*Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute; 2023 Apr 19. [updated: 2023 Jun 8; cited 2023 Sep 16]. Available from: \u3008https:\/\/seer.cancer.gov\/statistics-network\/explorer\/\u3009. Data source(s): SEER Incidence Data, November 2022 Submission (1975-2020), SEER 22 registries. Accessed September 6, 2023. \u3008https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html\u3009."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104557_bib52","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.4143\/crt.2020.1356","article-title":"Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study","volume":"53","author":"Shi","year":"2021","journal-title":"Cancer Res Treat."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104557_bib53","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0090-4295(02)01650-3","article-title":"Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer","volume":"60","author":"Shipley","year":"2002","journal-title":"Urology"},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104557_bib54","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.1998.16.11.3576","article-title":"Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03","volume":"16","author":"Shipley","year":"1998","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104557_bib55","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1111\/ajco.12351","article-title":"Efficacy and safety of late-course hypofractionated radiation therapy for muscle-invasive bladder carcinoma after bladder-conserving surgery","volume":"13","author":"Song","year":"2017","journal-title":"Asia Pac. J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104557_bib56","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.ijrobp.2021.03.001","article-title":"Long-Term Outcomes of Radical Radiation Therapy with Hypoxia Modification with Biomarker Discovery for Stratification: 10-Year Update of the BCON (Bladder Carbogen Nicotinamide) Phase 3 Randomized Trial (ISRCTN45938399)","volume":"110","author":"Song","year":"2021","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104557_bib57","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1200\/JCO.1996.14.1.119","article-title":"Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802","volume":"14","author":"Tester","year":"1996","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104557_bib58","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/0360-3016(93)90306-G","article-title":"Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12","volume":"25","author":"Tester","year":"1993","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104557_bib59","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.ijrobp.2016.11.040","article-title":"Tolerability of Concurrent Chemoradiation Therapy With Gemcitabine (GemX), With and Without Prior Neoadjuvant Chemotherapy, in Muscle Invasive Bladder Cancer","volume":"97","author":"Thompson","year":"2017","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104557_bib60","doi-asserted-by":"crossref","first-page":"e457","DOI":"10.1016\/j.ijrobp.2011.05.051","article-title":"Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience","volume":"82","author":"Tunio","year":"2012","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104557_bib61","first-page":"6","article-title":"Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer: experience at Sindh Institute of Urology & Transplantation (SIUT)","volume":"61","author":"Tunio","year":"2011","journal-title":"J Pak Med Assoc."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104557_bib62","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eururo.2005.04.005","article-title":"Adjuvant Chemotherapy in Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration","volume":"48","author":"Vale","year":"2005","journal-title":"Eur. Urol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104557_bib63","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/(SICI)1097-0142(19980301)82:5<918::AID-CNCR17>3.0.CO;2-3","article-title":"Rapidly alternating chemotherapy and radiotherapy instead of cystectomy for the treatment of muscle-invasive carcinoma of the urinary bladder: long term results of a pilot study","volume":"82","author":"Vikram","year":"1998","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104557_bib64","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.suronc.2016.05.027","article-title":"A systematic review and meta-analysis of quality of life outcomes after radical cystectomy for bladder cancer","volume":"25","author":"Yang","year":"2016","journal-title":"Surg. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104557_bib65","doi-asserted-by":"crossref","first-page":"517","DOI":"10.31557\/APJCP.2023.24.2.517","article-title":"Trimodality Therapy in which Concurrent Chemoradiation with Concomitant Boost in Muscle Invasive TCC Urinary Bladder Cancer","volume":"24","author":"Youssief Mohammed","year":"2023","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104557_bib66","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.urology.2012.07.045","article-title":"Long-term results of two prospective bladder-sparing trimodality approaches for invasive bladder cancer: neoadjuvant chemotherapy and concurrent radio-chemotherapy","volume":"80","author":"Zapatero","year":"2012","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104557_bib67","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104557_bib68","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/ijc.1034","article-title":"Invasive bladder carcinoma: a pilot study of conservative treatment with accelerated radiotherapy and concomitant cisplatin","volume":"96","author":"Zouhair","year":"2001","journal-title":"Int J. Cancer"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824003007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824003007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T03:22:57Z","timestamp":1734405777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842824003007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":68,"alternative-id":["S1040842824003007"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104557","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concomitant chemotherapy in trimodal treatment of patients with muscle invasive bladder cancer: A systematic review of prospective trials","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104557","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104557"}}